<DOC>
	<DOC>NCT02063789</DOC>
	<brief_summary>Human immunoglobulin (Ig) is the most commonly used blood product. It has been well-defined the efficacy in patients with immunodeficiencies, Kawasaki disease, asthma and other immune diseases. It is expected that Ig 10% will improve the usefulness and safety profile compared to Ig 5% because it is expected the reduced hospitalization/treatment duration and less adverse events related to volume overload.</brief_summary>
	<brief_title>An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia</brief_title>
	<detailed_description>GC5107A (IV-Globulin SN Inj. 10%) is a polyvalent intravenous human immunoglobulin G preparation. It is prepared from plasma collected from more than 1000 healthy blood donors and it expresses the large spectrum of antibody specificity.</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Given written informed consent Male or female aged â‰¥ 19 Primary immune thrombocytopenia (ITP) Platelet &lt;20x10^9 /L Patients who have taken adrenal cortical hormones and/or other immunosuppressive medications should maintain their stable doses before and during this study Patients who have participate in other interventional study within 30 days Inability in written/verbal communication Engaged with an elective surgery Pregnant or breastfeeding women Women of childbearing potential who do not agree with contraception during this study Patients who had experienced any hypersensitivity or shock with study drug or active ingredient Refractory to immunoglobulin therapy Secondary immune thrombocytopenia HIVassociated ITP Lupusassociated ITP Lymphproliferative disease Hepatitis virus carrier Other disease or infectionassociated ITP DrugInduced ITP Hereditary thrombopenia (e.g., MYH9 disorders) Hemolytic anemia (Positive direct Coomb's test) Clinically significant abnormalities of immunoglobulin Immunoglobulin A Deficiency Immune disorders or deficiency Alcohol or drug abuse within 6 months Patients who had taken any medications which may effect platelet function or count for at least 2 days prior study entry Patients who had administrated with IVIg or antiD immunoglobulin agents within 1 month Patients who had undergone a splenectomy within 2 months Clinically significant underlying disease or medical history at investigator's discretion</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Immune Thrombocytopenia</keyword>
	<keyword>Immune Thrombocytopenic Purpura</keyword>
	<keyword>Idiopathic Thrombocytopenic Purpura</keyword>
	<keyword>Human Immunoglobulin</keyword>
	<keyword>ITP</keyword>
	<keyword>IVIg</keyword>
	<keyword>IgIV</keyword>
	<keyword>IV-Globulin SN Inj.</keyword>
</DOC>